In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drug…
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more sa…
It’s a busy day at the FDA today as panels meet to discuss two new drugs — one to help weight loss and the other to combat drug addiction — and decide whether to approve AstraZeneca’s new blood thinner medication.
…